Companies › Almirall
6 active drug programs in 7 registered trials: 3 Phase 2, 2 Phase 3, 1 Phase 1, 1 Phase 4; Immunology, Other, Infectious disease; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tirbanibulin Tyrosine-protein kinase SRC inhibitor | SRC | Phase 4 | Keratosis, Actinic | Jul 2027 |
| Lebrikizumab Interleukin-13 inhibitor | IL13 | Phase 3 | Dermatitis, Atopic; Nummular Eczema | Apr 2027 |
| LAD328 Unclear mechanism | – | Phase 2 | Hidradenitis Suppurativa | Feb 2027 |
| LAD191 | – | Phase 2 | Hidradenitis Suppurativa | May 2027 |
| LAD603 JAK inhibitor | – | Phase 2 | Alopecia Areata | Jun 2027 |
| LAD106 | – | Phase 1 | Healthy Volunteers | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07547813 | LAD328 | Phase 2 | Hidradenitis Suppurativa | Infectious disease | Feb 2027 |
| NCT06526182 | Lebrikizumab | Phase 3 | Dermatitis, Atopic | Immunology | Apr 2027 |
| NCT07151937 | LAD191 | Phase 2 | Hidradenitis Suppurativa | Immunology | May 2027 |
| NCT07471932 | LAD106 | Phase 1 | Healthy Volunteers | Other | May 2027 |
| NCT07311564 | LAD603 | Phase 2 | Alopecia Areata | Immunology | Jun 2027 |
| NCT05387525 | Tirbanibulin | Phase 4 | Keratosis, Actinic | Immunology | Jul 2027 |
| NCT07542483 | Lebrikizumab | Phase 3 | Nummular Eczema | Immunology | Aug 2028 |
Eli Lilly Pfizer LEO Pharma AstraZeneca Nuvectis Pharma Turning Point Therapeutics The Skin Center Dermatology Group
Spyre Therapeutics LEO Pharma Arthrosi Therapeutics Sunshine Guojian Pharmaceutical (Shanghai) MRM Health
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.